| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Belite Bio Inc | Tinlarebant - (PHOENIX) | Geographic Atrophy (GA) | Phase 3 | Enrollment Initiation | Oral | Opthalmic |
| Belite Bio Inc | Tinlarebant - (DRAGON II) | Stargardt Disease | Phase 2/3 | Enrollment Initiation | Oral | #N/A |
| Belite Bio Inc | Tinlarebant (a/k/a LBS-008) | Adolescent STGD1 | Phase 2/3 | Trial Planned | Oral | Genetic Disorder |
| Belite Bio Inc | Tinlarebant - (LBS-008) | Dry Age-Related Macular Degeneration (AMD) | Phase 2/3 | Ongoing | Oral | Opthalmic |
| Bellerophon Therapeutics Inc. | INOpulse delivery device - (REBUILD) | Pulmonary hypertension associated with Fibrotic Interstitial Lung Disease | Phase 3 | Trial Discontinued | Inhalation | Respiratory |
| Bellerophon Therapeutics Inc. | INOpulse Inhaled Nitric Oxide | COVID-19 | Phase 3 | Inhalation | COVID-19 | |
| Bellerophon Therapeutics Inc. | INOpulse | Fibrotic interstitial lung disease (fILD) | Phase 3 | Trial Discontinued | Inhalation | Respiratory |
| Bellerophon Therapeutics Inc. | INOpulse | Pulmonary Hypertension-Sarcoidosis (PH-Sarc) | Phase 2 | Inhalation | Respiratory |